Fairvalue-Calculator Fairvalue-Calculator
EN DE

Bio-Gate AG (BIG1) Fair Value & Analysis

Healthcare · DE · Market cap €6.0M

Price€0.6250
Fair Value€0.5700
Upside-8.8%
Quality90/100
Evidence: Low Range €0.4300 – €0.7100

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Bio-Gate AG (BIG1) currently trades at €0.6250, while our model-based Fair Value estimate is €0.5700 — implying the stock looks roughly 8.8% overvalued today. We read business quality at 90/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Bio-Gate AG provides technologies and customized solutions for health and hygiene in Germany. The company offers HyProtect, a plasma coating which protects the surfaces of medical implants against bacterial colonization; and MicroSilver BG, an elemental microporous silver additive. It distributes its products to veterinarians and veterinary clinics. The company was incorporated in 2005 and is based in Nuremberg, Germany.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is Bio-Gate AG (BIG1) undervalued?
As of Jun 24, 2026, our model estimates a fair value of €0.5700 versus a price of €0.6250 — about −9% (overvalued). Model-based estimate, not financial advice.
What is the fair value of BIG1?
Our 21-model fair value for Bio-Gate AG is €0.5700 (as of Jun 24, 2026), built from audited fundamentals. The current price is €0.6250.
What is the quality score of BIG1?
Bio-Gate AG has a Quality Score of 90/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.